Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice (en anglais)

01 juin 2012

INTERNATIONAL JOURNAL OF ONCOLOGY 40: 1881-1888, 2012

ZONGQING TAN, PINGPING CHEN, NATHAN SCHNEIDER, SAMUEL GLOVER, LINGLING CUI, JULIEN TORGUE, OLIVIER RIXE, HENRY B. SPITZ and ZHONGYUN DONG

Abstract

The purpose of this study was to determine therapeutic effects and systemic toxicity of 212Pb-trastuzumab in an orthotopic model of human prostate cancer cells in nude mice. TCMC-Trastuzumab was radiolabeled with 212Pb. The 212Pb-trastuzumab generated from the procedure was intact and had high binding affinity with a dissociation constant (of 3.9±0.99 nM. PC-3MM2 cells, which expressed a lower level of HER2 both in culture and in tumors, were used in therapy studies. A single intravenous injection of 212Pb-trastuzumab reduced tumor growth by 60-80%, reduced aortic lymph node metastasis, and prolonged the survival of tumor-bearing mice. Treatment with 212Pb-trastuzumab did not cause significant changes in body weight, serum glutamic pyruvic transaminase (SGPT), blood urea nitrogen (BUN), hematological profiles, and histological morphology of several major organs of tumor-bearing mice. These findings suggest that a systemic delivery of 212Pb-trastuzumab could be an effective modality for management of advanced human prostate cancer.

To request a copy of the full article, please email alison.bedford@areva.com.

Vidéo AREVA Med

Cliquez ici pour voir la vidéo

Contact

Pour plus d'informations à propos d'AREVA Med, veuillez contacter :
Alison Tise
Tel.: + 1 (301) 841-1673